A phase II study of RP-L401
Latest Information Update: 06 Aug 2020
Price :
$35 *
At a glance
- Drugs RP L401 (Primary)
- Indications Osteopetrosis
- Focus Therapeutic Use
- Sponsors Rocket Pharmaceuticals
- 06 Aug 2020 New trial record
- 05 Aug 2020 According to a Rocket Pharmaceuticals media release, the study initiation is expected in 2021.